Izrael - angielski - Ministry of Health

novartis israel ltd - everolimus - tablets dispersible - everolimus 2 mg - everolimus - votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory epileptic seizures are associated with tuberous sclerosis complex (tsc).

Izrael - angielski - Ministry of Health

novartis israel ltd - everolimus - tablets dispersible - everolimus 3 mg - everolimus - votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory epileptic seizures are associated with tuberous sclerosis complex (tsc).

Izrael - angielski - Ministry of Health

novartis israel ltd - alpelisib - film coated tablets - alpelisib 150 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

Izrael - angielski - Ministry of Health

novartis israel ltd - alpelisib - film coated tablets - alpelisib 200 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

Izrael - angielski - Ministry of Health

novartis israel ltd - alpelisib - film coated tablets - alpelisib 50 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

Izrael - angielski - Ministry of Health

novartis israel ltd - brolucizumab - solution for injection - brolucizumab 120 mg / 1 ml - brolucizumab - beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (amd).

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - ofatumumab -

Izrael - angielski - Ministry of Health

novartis israel ltd - crizanlizumab - concentrate for solution for infusion - crizanlizumab 10 mg/ml - crizanlizumab - adakveo is indicated to reduce the frequency of vasoocclusive crises (vocs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - secukinumab -

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - secukinumab -